Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.

Tempus AI, Inc. Class A Common Stock

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. 

Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It’s About Time. 

For more information, visit tempus.com and follow us on Twitter (@TempusLabs). 

Tempus AI

Our founder and CEO, Eric Lefkofky, joins mHUB for next week's HardTech Summit to discuss his path to #AI enabled healthcare. Register here: https://tempus.co/4c2W6Q2 

Dr. Ezra Cohen’s personal passion for taking care of cancer patients led him from decades of clinical care and research to Tempus as our Chief Medical Officer of Oncology. In our #TempusWhy series, Dr. Cohen shares how our work at Tempus fuels his unwavering commitment and determination to advancing cancer care. 

Hear more: 

Physicians like Dr. James and their care teams seamlessly use Tempus One to make informed patient treatment decisions through convenient functionalities that deliver insights on patient’s full clinical and molecular profile. By improving clinical workflows, One can allow more time for teams to focus on patient care. Learn more about Tempus One: https://tempus.co/42ZDYT4 

We’re looking forward to being on-site this week at the Liquid Biopsy for Precision Oncology Summit. Attend Adam Morabito’s presentation on how emerging technologies and multi-modal data have unlocked novel use cases for tumor-naïve liquid biopsies. Learn more: https://tempus.co/4bIlHha 

We’re #NowHiring for a Territory Sales Executive to join our team in North Atlanta. This position will drive new opportunities with major US cancer centers, clinics, and oncology practices. Join our growing sales team by applying here: https://bit.ly/3T6HkjX #atljobs 

	Dec '21	Dec '22	Dec '23
net income	-259.19M -	-289.81M 11.81%	-214.12M 26.12%
depreciation and amortization	23.88M -	30.41M 27.34%	33.33M 9.61%
deferred income tax
stock based compensation	559K -
change in working capital	14.55M -	71.82M 393.57%	-37.84M 152.68%
accounts receivables	4.75M -	-8.20M 272.80%	-7.35M 10.44%
inventory	14.65M -	-1.31M 108.96%	-6.56M 400.23%
accounts payables	-30.47M -	-7.92M 74.03%	-23.36M 195.17%
other working capital	25.63M -	89.25M 248.23%	-26.41M 129.59%
other non cash items	67.62M -	97.63M 44.39%	16.89M 82.70%
net cash provided by operating activities	-211.98M -	-168.20M 20.65%	-214.34M 27.43%
investments in property plant and equipment	-11.77M -	-18.38M 56.17%	-34.61M 88.32%
acquisitions net	-5.96M -	-39.56M 564.13%	-5.71M 85.58%
purchases of investments	-5.96M -
sales maturities of investments
other investing activites	-4M -
net cash used for investing activites	-21.72M -	-57.94M 166.71%	-40.31M 30.42%
debt repayment	-796K -	-170.25M 21,288.19%	-82.59M 51.49%
common stock issued	8.89M -	92.20M 936.64%
common stock repurchased			-3.60M -
dividends paid	-5.63M -	-5.63M 0%	-5.63M 0%
other financing activites	-4.51M -	-5.43M 20.41%	-698K 87.15%
net cash used provided by financing activities	-2.04M -	251.39M 12,429.13%	117.55M 53.24%
effect of forex changes on cash	-3K -	17K 666.67%	-19K 211.76%
net change in cash	-235.75M -	25.25M 110.71%	-137.12M 643.02%
cash at beginning of period	513.44M -	277.69M 45.92%	303.73M 9.38%
cash at end of period	277.69M -	302.94M 9.09%	166.61M 45.00%
operating cash flow	-211.98M -	-168.20M 20.65%	-214.34M 27.43%
capital expenditure	-11.77M -	-18.38M 56.17%	-34.61M 88.32%
free cash flow	-223.75M -	-186.58M 16.61%	-248.95M 33.43%

TEM

COM:TEMPUS

Tempus

Last Close

52.48

22/11 21:00

Market Cap

5.77B

Beta: -

Volume Today

1.18M

Avg: -

Preview